Cardiovascular and renal outcomes with empagliflozin in heart failure (2020)
Source: New england journal of medicine. Unidade: FM
Subjects: ENVELHECIMENTO, DOENÇAS CARDIOVASCULARES, MORTALIDADE, PREVENÇÃO E CONTROLE, INSUFICIÊNCIA CARDÍACA, FISIOPATOLOGIA, INSUFICIÊNCIA RENAL CRÔNICA, HOSPITALIZAÇÃO
ABNT
PACKER, Milton et al. Cardiovascular and renal outcomes with empagliflozin in heart failure. New england journal of medicine, v. 383, n. 15, p. 1413-1424, 2020Tradução . . Disponível em: https://doi.org/10.1056/NEJMoa2022190. Acesso em: 31 out. 2024.APA
Packer, M., Anker, S. D., Butler, J., Filippatos, G., Pocock, S. J., Carson, P., et al. (2020). Cardiovascular and renal outcomes with empagliflozin in heart failure. New england journal of medicine, 383( 15), 1413-1424. doi:10.1056/NEJMoa2022190NLM
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Bocchi EA. Cardiovascular and renal outcomes with empagliflozin in heart failure [Internet]. New england journal of medicine. 2020 ; 383( 15): 1413-1424.[citado 2024 out. 31 ] Available from: https://doi.org/10.1056/NEJMoa2022190Vancouver
Packer M, Anker SD, Butler J, Filippatos G, Pocock SJ, Carson P, Januzzi J, Verma S, Tsutsui H, Bocchi EA. Cardiovascular and renal outcomes with empagliflozin in heart failure [Internet]. New england journal of medicine. 2020 ; 383( 15): 1413-1424.[citado 2024 out. 31 ] Available from: https://doi.org/10.1056/NEJMoa2022190